Recordati Rare Diseases

Recordati Rare Diseases is owned by CVC Capital Partners. CVC Capital Partners has a direct presence in 7 countries.

CVC Capital Partners has 15 subsidiaries including Breitling, CFGI and CVC Capital Partners Private Equity.

They are in:

• Fund19%
• Retail19%
• Other63%

View the org chart displaying its 11 main executives

Most searched biographies at Recordati Rare Diseases

• Luigi Longinotti, Managing Director and General Manager, EMEA
• William Ludlam, Chief Medical Officer and Vice President, Clinical...
• Scott Pescatore, Executive Vice President and Head of Global Opera...

Create your alert
to follow the executive moves at Recordati Rare Diseases.

CVC Capital Partners has 1,865 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Recordati Rare Diseases

Social media about Recordati Rare Diseases

• Recordati Rare Diseases on Wikipedia, Google News & Yahoo Finance
• Recordati Rare Diseases on LinkedIn, Twitter & YouTube

Contact by email its executives including Becky Zenz

Call Recordati Rare Diseases at +1 908...

View the org chart

Register to receive your alert

Report an error